JDRF CGM clinical trial published in the New England Journal of Medicine shows idividuals of all ages who use the device 6 days a week or more for 6 months, lower their A1c by at least .5 - lowering the statistical risk of developing microvascular complications approximately 25%. Review the EDIC follow up to the landmark DCCT trial. diabetic retinopothy is responsible for about 10,000 cases of blindness in the US every year. What is more important to you; money or sight.